-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target

Benzinga·11/06/2026 16:28:08
Guggenheim analyst Michael Schmidt reiterates Enliven Therapeutics (NASDAQ:ELVN) with a Buy and maintains $78 price target.